v3.26.3
Accrued expenses and other current liabilities - Additional information (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Dec. 31, 2025
Strategic reprioritization of clinical portfolio          
Accrued expenses and other current liabilities          
Percentage of workforce reduction 30.00%        
Cash expenditure for severance and other employee termination benefits $ 6.1        
Recognized charges   $ 0.3   $ 5.8  
Payments for restructuring       4.5  
Accrued restructuring costs   1.3   1.3  
Contract termination costs   0.0   3.9  
Strategic reprioritization of clinical portfolio | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense          
Accrued expenses and other current liabilities          
Restructuring charges   0.1   1.4  
Strategic reprioritization of clinical portfolio | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense          
Accrued expenses and other current liabilities          
Restructuring charges   $ 0.2   $ 4.4  
Cost reduction initiatives          
Accrued expenses and other current liabilities          
Recognized charges     $ 4.1    
Accrued restructuring costs         $ 0.3
Cost reduction initiatives | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense          
Accrued expenses and other current liabilities          
Restructuring charges     0.8    
Cost reduction initiatives | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense          
Accrued expenses and other current liabilities          
Restructuring charges     $ 3.3